Research programme: multiple sclerosis therapies - Syntonix Pharmaceuticals/Merck Serono
Alternative Names: interferon-beta:Fc; Interferon-β-FcLatest Information Update: 25 Feb 2008
Price :
$50 *
At a glance
- Originator Syntonix Pharmaceuticals
- Class Interferons; Recombinant fusion proteins
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 01 Feb 2007 Syntonix Pharmaceuticals has been acquired by Biogen Idec
- 08 Jan 2007 Serono is now called Merck Serono
- 05 Jan 2007 Serono has been acquired by Merck KGaA